CG Oncology, Inc. unveils five cretostimogene research posters at ASCO GU in San Francisco

CG Oncology, Inc. unveils five cretostimogene research posters at ASCO GU in San Francisco
CG Oncology, Inc. presents five posters

CG Oncology, Inc. has presented five new research posters focused on cretostimogene at the ASCO Genitourinary Cancers Symposium in San Francisco.

The posters draw from studies including CORE‑008 (A and B), BOND‑003 (C and P), and the company’s Expanded Access Program, highlighting ongoing scientific innovation in bladder cancer and genitourinary oncology. With this comprehensive update, CG Oncology, Inc. aims to reinforce its position in advancing novel therapies for the field. Further details on the research can be accessed through the provided links.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.